retatrutide trial Clinical – My Endo Consult Retatrutide produces up to 30.3%

As tirzepatide promotes substantial weight reductionclinical trials such as SURMOUNT-1 demonstrated average weight loss of approximately 20.9% of body weight at the 15 mg dose in adults without diabetesthis metabolic shift can influence the hypothalamic-pituitary-ovarian axis that regulates menstruation

Providing an uninterrupted supply of clean, safe drinking water

New obesity drug could change weight loss treatment For India, where long-term adherence is a major challenge, a once-monthly GLP-1 therapy could improve patient acceptance and sustained obesity management, says Dr Anoop Misra, Chairman at Fortis CDOC Hospital for Diabetes and Allied Sciences

About this article Cite this article Romariz, L.M., de Melo, A.A.C., Finnegan, E